🇮🇳 Sun Pharmaceutical Industries Ltd

Press Release 30-10-2026 08:05:37 IST

Overview: The U.S. FDA has approved the supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis.

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest